Investments
177Portfolio Exits
88Funds
4About Cormorant Asset Management
Cormorant Asset Management is a Boston-based investment manager with investment focus in both public and private market innovative companies in the biotechnology and life sciences marketplace.
Cormorant Asset Management Headquarter Location
Boston, Massachusetts,
United States
Expert Collections containing Cormorant Asset Management
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Cormorant Asset Management in 1 Expert Collection, including Synthetic Biology.
Synthetic Biology
382 items
Research containing Cormorant Asset Management
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Cormorant Asset Management in 2 CB Insights research briefs, most recently on Aug 5, 2021.
Aug 5, 2021
Here Are The Most Active Healthcare Investors
May 20, 2020
Here Are Q1’s Most Active Healthcare InvestorsLatest Cormorant Asset Management News
Apr 21, 2022
US biotech firm Tessera Therapeutics, which is pioneering a new approach in genetic medicine known as GENE WRITING technology, has raised over $300 million in Series C financing. Investors included a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA); Alaska Permanent Fund Corporation; Altitude Life Science Ventures; ARTIS Ventures; Cormorant Asset Management; Tessera’s founder, Flagship Pioneering; Hanwha Impact Partners; Longevity… This article is accessible to registered users, to continue reading please register for free . A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login . If your trial has come to an end, you can subscribe here. • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. • Daily roundup of key events in pharma and biotech. • Monthly in-depth briefings on Boardroom appointments and M&A news. • Choose from a cost-effective annual package or a flexible monthly subscription. If you are already a registered user please login . The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed Chairman, Sanofi Aventis UK
Cormorant Asset Management Investments
177 Investments
Cormorant Asset Management has made 177 investments. Their latest investment was in MOMA Therapeutics as part of their Series B on May 5, 2022.
Cormorant Asset Management Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
5/10/2022 | Series B | MOMA Therapeutics | $150M | No | 7 | |
4/29/2022 | Series B | Adona Medical | $37.5M | No | 2 | |
4/19/2022 | Series C | Tessera Therapeutics | $300M | Yes | 3 | |
3/1/2022 | Series C | |||||
2/16/2022 | Series B |
Date | 5/10/2022 | 4/29/2022 | 4/19/2022 | 3/1/2022 | 2/16/2022 |
|---|---|---|---|---|---|
Round | Series B | Series B | Series C | Series C | Series B |
Company | MOMA Therapeutics | Adona Medical | Tessera Therapeutics | ||
Amount | $150M | $37.5M | $300M | ||
New? | No | No | Yes | ||
Co-Investors | |||||
Sources | 7 | 2 | 3 |
Cormorant Asset Management Portfolio Exits
88 Portfolio Exits
Cormorant Asset Management has 88 portfolio exits. Their latest portfolio exit was Affinivax on May 31, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
5/31/2022 | Acquired | 6 | |||
2/3/2022 | Reverse Merger | 3 | |||
1/7/2022 | IPO | Public | 7 | ||
Date | 5/31/2022 | 2/3/2022 | 1/7/2022 | ||
|---|---|---|---|---|---|
Exit | Acquired | Reverse Merger | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 6 | 3 | 7 |
Cormorant Asset Management Fund History
4 Fund Histories
Cormorant Asset Management has 4 funds, including Cormorant Private Healthcare Fund IV.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
8/4/2021 | Cormorant Private Healthcare Fund IV | $253M | 1 | ||
7/14/2020 | Cormorant Private Healthcare Fund III | ||||
7/14/2020 | Cormorant Private Healthcare Offshore Fund III | ||||
Cormorant Private Healthcare Offshore Fund I LP |
Closing Date | 8/4/2021 | 7/14/2020 | 7/14/2020 | |
|---|---|---|---|---|
Fund | Cormorant Private Healthcare Fund IV | Cormorant Private Healthcare Fund III | Cormorant Private Healthcare Offshore Fund III | Cormorant Private Healthcare Offshore Fund I LP |
Fund Type | ||||
Status | ||||
Amount | $253M | |||
Sources | 1 |
Cormorant Asset Management Team
5 Team Members
Cormorant Asset Management has 5 team members, including current Chief Executive Officer, Managing Director, Bihua Chen.
Name | Work History | Title | Status |
|---|---|---|---|
Bihua Chen | Putnam Investments | Chief Executive Officer, Managing Director | Current |
Jay Scollins | Bain Capital, Sankaty Advisors, and Ernst & Young | Chief Financial Officer, Chief Operating Officer | Current |
Raymond J Kelleher | Managing Director | Current | |
Andrew Phillips | Managing Director | Current | |
Kelsey Chen | Managing Director | Former |
Name | Bihua Chen | Jay Scollins | Raymond J Kelleher | Andrew Phillips | Kelsey Chen |
|---|---|---|---|---|---|
Work History | Putnam Investments | Bain Capital, Sankaty Advisors, and Ernst & Young | |||
Title | Chief Executive Officer, Managing Director | Chief Financial Officer, Chief Operating Officer | Managing Director | Managing Director | Managing Director |
Status | Current | Current | Current | Current | Former |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.